MaHRC’s vision is to contribute with interdisciplinary research to new knowledge on music’s role to strengthen the achievement of these goals.Ī second vision of MaHRC is to become an international platform for building networks of inter-disciplinary research teams through collaborations, conferences, colloquia, workshops, media, and other forms of knowledge exchange.Ī third vision of MaHRC is to become an international platform for the transmission and dissemination of research outcomes to clinicians, practitioners, teachers, and the public to benefit clinical practice and people’s health.
LTO-Aim 4: Estimate current and future health system needs to address long-term effects of SARS-CoV-2įor more information on VA research projects related to COVID-19: Participating in ResearchĪnyone over the age of 18, including Veterans, their friends and family of Veterans, and VA staff can participate in VA national COVID-19 research efforts by registering at vision of MaHRC is aligned with the Strategic Research Plan of the University of Toronto – in particular with point (1): Promote Healthy People, Healthy Communities, and a Healthy World through music, and point (2): Engage Minds, Culture, and Values. LTO-Aim 3: Elicit Veteran experiences of recovery after SARS-CoV-2 infection through semi-structured interviews. LTO-Aim 2: Compare VHA patients infected and uninfected by SARS-CoV-2 on veteran-reported outcomes, including as self-reported symptoms, disability, informal caregiving receipt, and financial impacts. LTO-Aim 1: Compare VHA patients infected and uninfected with SARS-CoV-2 on outcomes that can be measured in electronic health records and claims datasets, such as mortality, hospital readmissions, new and exacerbated conditions, and new mental health conditions. By triangulating a range of data sources, the LTO will: The LTO will be responsible for carrying out a rigorous mixed methods study of the long-term effects of SARS-CoV-2 infection on Veterans, with support from the CC. CC-Aim 5: Describe incidence and predictors of key long-term adverse outcomes and manifestations of SARS-CoV-2 infection. CC-Aim 4: Understand the medical and non-medical effects of SARS-CoV-2 by comparing clinical, economic, and patient- reported outcomes between SARS-CoV-2 infected and uninfected VHA patients. CC-Aim 3: Provide methodologic guidance and support to VA investigators and operational partners. CC-Aim 2: Generate and disseminate documentation of matched comparators, exposures, outcomes, and covariates. CC-Aim 1: Develop a data infrastructure to support dynamic analytic datasets of SARS-CoV-2 infected and uninfected comparator cohorts that will facilitate research on a broad range of VHA health record-based outcomes. The 3 pillars of the CC are a Data Core, Methods Core, and Partnerships Core, which will work together to carry out the following aims: To improve Veteran’s health by conducting and supporting rigorous research to understand the long-term effects of SARS-CoV-2 infection while fostering research collaborations within and outside of the Department of Veterans Affairs. Federal-wide Research Performance Progress Report. Find VA-sponsored clinical trials near you. Alzheimer's Disease and Related Dementias. NIH Manuscript Submission for VA Investigators. ORD VHA Directives, Handbooks, and Program Guides. VA Informatics and Computing Infrastructure (VINCI). VA SHIELD (Central Biospecimen and Data Repository). Gulf War Veterans' Illnesses Biorepository. VA Electronic Determination Aid (VAEDA). VA Innovation and Research Review System (VAIRRS). Office of Research Protections, Policy, and Education (ORPP&E). National Artificial Intelligence Institute (NAII). Diversity, Equity, and Inclusion Initiative (DEI). Centralized Interactive Phenomics Resource (CIPHER). Center for Data & Computational Science (C-DACS). 
Letters and Op-eds Concerning VA Research with Animals.
National Academy of Sciences Assessment. 
Currently Approved VA Protocols for Research.Distinguished Medical Research Scientist.COVID-19 Observational Research Collaboratory.
0 kommentar(er)
